Barclays analyst Andrew Mok lowered the firm’s price target on Universal Health (UHS) to $249 from $271 and keeps an Overweight rating on the shares post the Q4 report. The company reported a solid beat while absorbing higher malpractice costs and guided to 5%-11% EBITDA growth without any contribution from new state supplemental programs, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Closing Bell Movers: Snowflake up 11%, Nvidia little changed after earnings
- Universal Health reports Q4 adjusted EPS $4.92, consensus $4.18
- Universal Health sees FY25 EPS $18.45-$19.95, consensus $18.16
- Notable companies reporting after market close
- UHS Earnings Report this Week: Is It a Buy, Ahead of Earnings?